Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » CareDx, Veracyte to Commercialize Organ Transplant Rejection Tests on nCounter Platform

CareDx, Veracyte to Commercialize Organ Transplant Rejection Tests on nCounter Platform

May 14, 2020
|
staff reporter

NEW YORK – CareDx and Veracyte said on Thursday that they have signed an agreement to make CareDx the exclusive worldwide commercialization partner for solid organ transplant rejection tests on Veracyte's nCounter Flex Analysis diagnostic platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

More Details Wanted

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

And a Third

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

Glimpses of Viral Origins

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

PLOS Papers on Plasmodium Falciparum Populations, Scabies Molecular Diagnostics, More

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.

What's Popular?

In Business News

  1. Hologic Acquires European MDx Firm Diagenode for Approximately $159M

  2. GenMark Diagnostics Seeing Continued Demand for Respiratory Panels, Plans 510(k) Submission

    Premium

  3. People in the News: New Appointments at Qiagen, ImmunoScape, 908 Devices, More

  4. Luminex Shares Surge on Rumor of Acquisition by DiaSorin

  5. Guardant Health Begins First Foray Into Early-Stage Cancer With Commercial MRD Test Launch

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.